区域与医院及患者特征对美国医保受益人心肌梗死后高强度他汀使用的影响
该回顾性队列分析纳入139 643例66岁及以上因心肌梗死住院的医保受益人,评估区域、医院和患者特征与出院后高强度他汀使用的关系。2011至2015年高强度他汀使用从23.4%升至55.6%,但区域差异持续存在;区域是最强相关因素,新英格兰地区使用率比西中南地区高66%(RR 1.66;95%CI 1.47-1.87)。
要点
- 心肌梗死后高强度他汀使用从2011年23.4%增至2015年55.6%,但区域差异持续。
- 区域是高强度他汀使用的最强相关因素,新英格兰比西中南地区高66%。
- 医院规模≥500床、医学院附属、男性、置入支架与更高使用相关。
核心结论
- 地理区域是心肌梗死后高强度他汀使用的最强相关因素,导致大规模治疗差异。
研究设计与样本
- 回顾性队列分析,使用Medicare行政索赔和参保数据,纳入2011年1月1日至2015年6月30日因心肌梗死住院、出院30天内有他汀处方索赔的66岁及以上按服务收费受益人,共139 643例。
主要发现
- 高强度他汀总体使用从2011年23.4%增至2015年55.6%,但区域间治疗差距持续存在。
- 在考虑区域及患者和医院特征的模型中,区域是最强相关因素,新英格兰使用率比西中南地区高66%(RR 1.66;95%CI 1.47-1.87)。
- 医院规模至少500床(RR 1.15;95%CI 1.07-1.23)、医学院附属(RR 1.11;95%CI 1.05-1.17)、男性(RR 1.10;95%CI 1.07-1.13)和患者接受支架(RR 1.35;95%CI 1.31-1.39)与更高高强度他汀使用相关。
- 营利性医院所有权、患者年龄大于75岁、既往冠状动脉疾病和其他合并症与更低使用相关。
关键数值与推荐
- 高强度他汀定义为出院后首个他汀索赔为阿托伐他汀钙40-80 mg或瑞舒伐他汀钙20-40 mg/d,低至中等强度为其他他汀类型和剂量。
临床怎么用
- 临床医生应认识到心肌梗死后高强度他汀使用存在区域和医院层面差异,在处方时关注患者和医院特征可能带来的治疗不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-intensity statin use after myocardial infarction (MI) varies by patient characteristics, but little is known about differences in use by hospital or region. OBJECTIVE: To explore the relative strength of associations of region and hospital and patient characteristics with high-intensity statin use after MI. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used Medicare administrative claims and enrollment data to evaluate fee-for-service Medicare beneficiaries 66 years or older who were hospitalized for MI from January 1, 2011, through June 30, 2015, with a statin prescription claim within 30 days of discharge. Data were analyzed from January 4, 2017, through May 12, 2019. EXPOSURES: Beneficiary characteristics were abstracted from Medicare data. Hospital characteristics were obtained from the 2014 American Hospital Association Survey and Hospital Compare quality metrics. Nine regions were defined according to the US Census. MAIN OUTCOMES AND MEASURES: Intensity of the first statin claim after discharge characterized as high (atorvastatin calcium, 40-80 mg, or rosuvastatin calcium, 20-40 mg/d) vs low to moderate (all other statin types and doses). Trends in high-intensity statins were examined from 2011 through 2015. Associations of region and beneficiary and hospital characteristics with high-intensity statin use from January 1, 2014, to June 15, 2015, were examined using Poisson distribution mixed models. RESULTS: Among the 139 643 fee-for-service beneficiaries included (69 968 men [50.1%] and 69 675 women [49.9%]; mean [SD] age, 76.7 [7.5] years), high-intensity statin use overall increased from 23.4% in 2011 to 55.6% in 2015, but treatment gaps persisted across regions. In models considering region and beneficiary and hospital characteristics, region was the strongest correlate of high-intensity statin use, with 66% higher use in New England than in the West South Central region (risk ratio [RR], 1.66; 95% CI, 1.47-1.87). Hospital size of at least 500 beds (RR, 1.15; 95% CI, 1.07-1.23), medical school affiliation (RR, 1.11; 95% CI, 1.05-1.17), male sex (RR, 1.10; 95% CI, 1.07-1.13), and patient receipt of a stent (RR, 1.35; 95% CI, 1.31-1.39) were associated with greater high-intensity statin use. For-profit hospital ownership, patient age older than 75 years, prior coronary disease, and other comorbidities were associated with lower use. CONCLUSIONS AND RELEVANCE: This study's findings suggest that geographic region is the strongest correlate of high-intensity statin use after MI, leading to large treatment disparities.
引用
- Bittner V, Colantonio LD, Dai Y, et al. Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries. JAMA Cardiol. 2019. PMID: 31339519. doi:10.1001/jamacardio.2019.2481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。